<DOC>
	<DOCNO>NCT00537056</DOCNO>
	<brief_summary>To learn whether FDG PET/CT DCE MRI well predictor response therapy current standard care ( CT MRI ) .</brief_summary>
	<brief_title>Evaluating Sunitinib Therapy Renal Cell Carcinoma Using F-18 FDG PET/CT DCE MRI</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Measurable disease RECIST criterion Pathologic diagnosis renal cell cancer Advanced ( stage IV ) renal cell cancer Karnofsky performance status ( KPS &gt; 70 ) Consent participate clinical trial Patients complete PET/CT scan . Pregnant woman . Healthy volunteer . Patients participate research protocol exclude study . Metallic implant ( prosthesis , ICD , pacemaker ) , since contraindication MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>